|
|
|
 |
 |
|
       |
|
|
|
Publications Using PSC Products  Journal Articles that use PSC Research Antigens Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. Treanor, J.J. et al. JAMA. 2007 Apr 11;297(14):1577-82. Dose-Related Safety and Immunogenicity of a Trivalent Baculovirus-Expressed Influenza-Virus Hemagglutinin Vaccine in Elderly Adults. Treanor, J.J et al; Journal of Infectious Diseases 2006: 193 Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenographs in mice Allegrini, G. et al; Journal of Cancer Chemotherapy Pharmacology, 2004; Vol. 53: 261-266 Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load Harari, A. et al; The European Journal of Immunology, 2004; Vol. 34 Hepatitis C Virus and HIV Envelope Proteins Collaboratively Mediate Interleukin-8 Secretion through Activation of p38 MAP Kinase and SHP2 in Hepatocytes Balasubramanian, A. et al; The Journal of Biological Chemistry, 2003; Vol. 37: 35755-35766 Hepatitis C and Human Immunodeficiency Virus Envelope Proteins Cooperatively Induce Hepatocytic Apoptosis via an Innocent Bystander Mechanism Munshi, N. et al; The Journal of Infectious Diseases, 2003; Vol. 188: 1192-204 Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1 infected subjects with progressive disease: changes after antiretroviral therapy. Harari, A. et al; Blood, 2004, Vol. 103.3, 966-972 Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Tumpey, T.M. et al; PNAS Presence of Human Immunodeficiency Virus-1-Specific CD4 and CD8 Cellular Immune Responses in Children with Full or Partial Virus Suppression. Papasavvas, E. et al; The Journal of Infectious Diseases, 2003, Vol. 188, 873-882 CXCR4/CCR5 Down-modulation and Chemotaxis Are Regulated by the Proteasome Pathway Fernandis, A.Z. et al; The Journal of Biological Chemistry, 2002; Vol. 277: 18111-18117 Analysis of HIV-1 and CMV-specific memory CD4 T-cell responses during primary and chronic infection. Harari, A. et al; Blood, 2002, Vol. 100, 1381-1387 Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. Rizzardi, G.P. et al; The Journal of Clinical Investigation, 2002, Vol. 109.5, 681-688 Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. Garcia, F. et al; AIDS, 1999, Vol. 13(11), F79-86 A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1 infected patients in very early stage disease: the Spanish Earth -1 Study. Garcia, F.et al; AIDS, 1999, Vol. 13(17), 2377-2388 HIV-1 specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR-phenotype: comparison of statistical methods for measurement. Lubaki, N.M.; J. AIDS, 1999, Vol. 22(1), 19-30 Theraputic immunization with recombinant gp160 in HIV-1 infection: a randomized double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Sandstrom, E., Wahren, B.; Lancet, 1999, Vol. 353, 1735-1742. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study. Plana, M.; Lancet, 1998, Vol. 352(9135), 1194-1195. Apoptosis in asymptomatic HIV-1 seropositives immunized with HIV-1 env glycoprotein (gp160): effects of administration of Zidovudine in vivo and interleukin-2 in vitro. Piedominici, M. et al; Vaccine, 1998, Vol. 16(7), 715-721. Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting. McElrath, M.J. et al; Journal of Infectious Diseases, 1994, Vol. 169, 41-47. Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160. Kovacs, J.A. et al; Journal of Clinical Investigation, 1993, Vol. 92, 919-928. |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
